Cyproheptadine Hydrochloride 1.5mg + Tricholine Citrate 55mg in Flavoured Sorbitol Base is a liquid pharmaceutical preparation based on a flavoured sorbitol medium containing two active ingredients. The product formulation can be made while controlling the active ingredients for controlled handling, accurate dispensing, uniform distribution, suitable viscosity and filling. For companies looking to build a diverse liquid formulation portfolio to expand a PCD Pharma Franchise range, this active ingredients liquid preparation can be added to the category range under systematic product development.
The use of a sorbitol based liquid vehicle provides scope for a defined formulation to solubilize and support the active ingredients with other excipients as necessary. Flavouring components can be added to create the desired finished flavour profile for the product specification. Manufacturing controls may focus on the compatibility of active ingredients and excipients, homogeneity, pH, viscosity, microbial quality, fill volume and stability.
Preparation of the medicament can begin with the qualification of the active ingredients, Cyproheptadine Hydrochloride, and Tricholine Citrate. Each active can be evaluated against its dedicated raw-material specification prior to batch release for formulation work. Typical tests may include identity, assay, purity, moisture content and other relevant tests depending on the drug product.
Accurate dispensing is critical as the two active ingredients are present at substantially different quantities in the medicine. Cyproheptadine Hydrochloride 1.5mg and Tricholine Citrate 55mg are combined to produce a ready-mixed formulation, with controlled weighing and dispensing procedures employed to maintain proportions. The API positioning in a patient-ready formulation can be maintained according to the actual final formulation
The sorbitol base and other formulation components can be qualified, as appropriate. Depending on the ultimate formulation, ingredients may include water, flavouring agents, viscosity-controlling agents, preservatives, sweetening agents and other suitable excipients.
Compatibility studies can be undertaken during formulation work to assess the interactions of the APIs and excipients including sorbitol base and flavouring system, with each other. The established pharmaceutical formula can be maintained according to approved finished product specifications.
Preparation of the sorbitol base may be a key aspect of manufacture. Sorbitol and other liquid excipients can be processed within a defined sequence and with controlled parameters.
The active ingredients can be incorporated into the finished vehicle by careful addition and mixing with controlled speed and order, temperature and time to achieve uniformity. Premixing or diluting measures can be incorporated to create a uniform bulk formulation for the relatively low Dose of Cyproheptadine Hydrochloride 1.5mg, with dispersion through the bulk.
Tricholine Citrate can be incorporated at the specified quantity within the approved formulation sequence. Agitation may be continuous or intermittent where required to prevent phase separation or stratification. In-process controls may include visual appearance, colour, odour, pH, viscosity, and specific gravity. Filtration of bulk liquid prior to filling can be an option in some formulations.
The flavouring system may be added according to standardised formulation requirements, to support the desired product flavour. Compatibility with other formulation components should be maintained.
Once formulation controls are met, the bulk preparation may be transferred to a liquid filling line and filled into approved packaging mediums. Displacement fill volumes should be maintained by equipment calibration and inspection before and during the manufacturing run, in order to prevent variances. Line clearance procedures can be employed to prevent mix-ups between formulations.
Suitable pharmaceutical grade bottles, closures, tamper-evident seals, and other packaging components should be employed. The final pack can be inspected and filled units checked for correct fill volume. Any container-closure combination may be tested for integrity.
Final product packaging can include using labels or printed cartons with the product name, composition, batch number, manufacturing site information, suggested expiry period, storage conditions, and other requirements.
Quality control may include testing raw materials, finished bulk and filled units. Finished product specification may include testing for identification, assay of active ingredients, visual appearance, odour, colour, pH, viscosity, specific gravity, fill volume, microbial cleanliness, and other parameters.
Distribution through qualified packaging mediums should be considered along with appropriate analytical validation or verification for any test procedures used. Organoleptic qualities of colour, odour, and taste may also be of interest.
Testing of stable samples from storage studies can be undertaken according to monitored storage conditions to define a shelf life and highlight potential ingredient deterioration or product defect. Stability parameters of pH, viscosity, specific gravity, assay, and contaminant levels may all be considered.
Protective packaging should be used to safeguard the product quality in transit and storage. Suitable bottle materials and closure types can help to maintain the optimal vehicle pH and protect from undesired quality loss.
A company entering into a PCD Pharma Franchise system can develop a number of product variants which are based on the same pharmaceutical API combination. Cyproheptadine Hydrochloride 1.5mg + Tricholine Citrate 55mg in Flavoured Sorbitol Base can be listed as an additional member of a drug portfolio with a focus on liquid formulations. Controlled addition of ingredients and API, sorbitol base, and fragrance, together with controlled mixing, filling, storage and stability testing can allow regular manufacturing in an established system.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech